The patients in single arm open label extension study were given autologous stem cell transplant along with modified T cells.
The clinical trial, which enrolled 6 patients, aimed to evaluate the safety, bioactivity and antitumor effect of infusion of patients’ own T cells to express a high affinity T cell receptor (TCR) specific for a type of tumor antigen known as a cancer testis antigen,NYESO-1 and LAGE-1.
The study also included patients who have received prior treatment for myeloma or who have disease considered to be high risk, and who are eligible for an autologous stem cell transplant.
The clinical study chair Aaron Rapoport said, "From a clinical perspective, I am encouraged by these preliminary findings which will enable us to continue to evaluate T cell therapy for myeloma, and I look forward to the opportunity to present the data for review in a national forum."
Adaptimmune Medical Director Dominic Smethurst said, "We are working with a world class team of investigators, who are very engaged with ensuring the clinical advancement of this technology."